Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Solifenacin. If urinary tract infection is present, an appropriate antibacterial therapy should be started. Solifenacin should be used with caution in patients with: Angioedema and anaphylactic reactions: Reports of angioedema of the face, lips and/or larynx, in some cases occurring after the first dose, have been described. Anaphylactic reactions have been reported rarely.
Urinary Retention: Administer with caution to patients with clinically significant bladder outflow obstruction.
Gastrointestinal Disorders: Use with caution in patients with decreased gastrointestinal motility.
Central Nervous System Effects: Advise patients not to drive or operate heavy machinery until they know how UROCALM affects them.
Controlled Narrow-Angle Glaucoma: Use with caution in patients being treated for narrow-angle glaucoma.
QT Prolongation: Use with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.
Dose should not exceed 5mg for the patients with severe renal impairment (creatinine clearance ≤ 30 mL/min) moderate hepatic impairment (Child-Pugh score of 7 to 9).